SKYE has been in the news 900% more than usual
Oct 06, 2025, 6:32 PM
-8.44%
What does SKYE do
Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
SKYE has been in the news recently: Skye Bioscience Inc. (NASDAQ:SKYE) experienced a decline in stock value following the release of topline data from its 26-week Phase 2a study of nimacimab. Despite this, the company is associated with a broader trend of gainers reporting a 15% increase in revenue, indicating strong market performance in the second quarter.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.